Capdevila, J, Paez, D, Villacampa, MM, Garcia-Alvarez, A, Aparicio, J, Pampols, M, Riesco-Martinez, MD, Polo, E, Ruiz-Casado, A, Castañon, C, Soriano, S, Hernando, J, Navalpotro, B, Armario, D, Villacampa, G, Horvath, E, Virgili, AC, Asiain, L, Giménez, A, Guillot, M. Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(2_SUPPL)DOI:10.1200/JCO.2026.44.2_suppl.11. PMID:. IF:41.900(Q1/1D).

Hayes, M, Nakajima, TE, Seecof, O, Majem, M, Chenji, S, Ashki, N, Ceccarelli, M, Van Cutsem, E. A phase 2 randomized, double-blind, placebo-controlled study to evaluate LY3537021 for the treatment of chemotherapy-induced nausea and vomiting in patients with malignant disease.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(2_SUPPL)DOI:10.1200/JCO.2026.44.2_suppl.TPS855. PMID:. IF:41.900(Q1/1D).

Martín, AJM, Castet, F, Vera, R, Alvarez, R, Garcia-Alfonso, P, Alsar, JS, Palao, P, Diaz, IA, Vidal-Tocino, R, Adeva, J, Modrego, A, Maseda, AC, Martínez-Galán, J, Serda, PC, Rodriguez-Alonso, RM, Aranda, E, La Casta, A, de Castro, EM, Montes, AFF, Macarulla, T. Isocitrate dehydrogenase 1 mutations in biliary tract cancer patients in Spanish RETUD registry. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(2_SUPPL)DOI:10.1200/JCO.2026.44.2_suppl.500. PMID:. IF:41.900(Q1/1D).

Martín, AJM, Castet, F, Vera, R, Alvarez, R, Pertusa, C, Garcia-Alfonso, P, Rodríguez, RJ, Vidal-Tocino, R, Diaz, IA, Caro, NL, Adeva, J, Paladines, WGP, Maseda, AC, Rodriguez-Alonso, RM, Aranda, E, Serda, PC, de Castro, EM, La Casta, A, Laquente, B, Macarulla, T. ERBB2/HER2 status in biliary tract cancer patients in the Spanish RETUD registry.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(2_SUPPL)DOI:10.1200/JCO.2026.44.2_suppl.498. PMID:. IF:41.900(Q1/1D).

Alonso-Gordoa, T, Anguera, G, Domínguez-Esteban, M, Reig, O, Martínez-Barros, H, Molina-Cerrillo, J, Cruz, P, Maroto, P. Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies. CANCER TREATMENT REVIEWS. 2025; 136DOI:10.1016/j.ctrv.2025.102925. PMID:40186886. IF:10.500(Q1/1D).

Favaro, MTP, Alamo, P, Roher, N, Chillon, M, Lascorz, J, Márquez, M, Corchero, JL, Mendoza, R, Martínez-Torró, C, Ferrer-Miralles, N, Ferreira, LCS, Mangues, R, Vázquez, E, Parladé, E, Villaverde, A. Zinc-Assisted Microscale Granules Made of the SARS-CoV-2 Spike Protein Trigger Neutralizing, Antivirus Antibody Responses. ACS Materials Letters. 2024; 6(3)DOI:10.1021/acsmaterialslett.3c01643. PMID:. IF:8.700(Q1/2D).

Vergouwen, MDI, Ramos-Pachon, A, Terecoasa, EO, Willett, N, Cuadrado-Godia, E, Gaberel, T, Gizewski, ER, Helbok, R, Ho, LA, Hugelshofer, M, Korja, M, Meling, TR, Psychogios, MN, Rinkel, GJE, Taschner, CA, Vajkoczy, P, Etminan, N. European Stroke Organisation (ESO), European Association of Neurosurgical Societies (EANS) and European Society for Minimally Invasive Neurological Therapy (ESMINT) guideline on aneurysmal subarachnoid haemorrhage. European Stroke Journal. 2026; 11(5)DOI:10.1093/esj/aakag043. PMID:42095754. IF:4.500(Q1/2D).

Lambea-Gil, A, Camps-Renom, P, Martí-Fàbregas, J, Guasch-Jiménez, M, Ezcurra-Díaz, G, Fernández-Vidal, JM, Prats-Sanchez, L, Martínez-Domeño, A, de la Ossa, NP, Ramos-Pachón, A. Early care limitation after ICH in a population-based study: what drives clinicians' decisions?. European Stroke Journal. 2026; 11(4)DOI:10.1093/esj/aakag028. PMID:41947561. IF:4.500(Q1/2D).